Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.36 -0.02 (-4.38%)
Closing price 04/25/2025 03:58 PM Eastern
Extended Trading
$0.39 +0.03 (+7.78%)
As of 04/25/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.34
$0.37
50-Day Range
$0.35
$0.61
52-Week Range
$0.19
$3.16
Volume
129,717 shs
Average Volume
470,379 shs
Market Capitalization
$1.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Entero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

ENTO MarketRank™: 

Entero Therapeutics scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Entero Therapeutics.

  • Percentage of Shares Shorted

    9.51% of the float of Entero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entero Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entero Therapeutics has recently increased by 262.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Entero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Entero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.51% of the float of Entero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entero Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entero Therapeutics has recently increased by 262.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Entero Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Entero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.49% of the stock of Entero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 12.30% of the stock of Entero Therapeutics is held by institutions.

  • Read more about Entero Therapeutics' insider trading history.
Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

Entero Therapeutics Delays 10-K Filing
Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Entero Therapeutics names Richard Paolone as interim CEO
Entero Therapeutics Appoints Richard Paolone as CEO
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $0.6220 on January 1st, 2025. Since then, ENTO shares have decreased by 42.1% and is now trading at $0.36.
View the best growth stocks for 2025 here
.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), Elevai Labs (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Today
4/26/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.31 per share
Price / Book
0.16

Miscellaneous

Free Float
4,731,000
Market Cap
$1.72 million
Optionable
N/A
Beta
0.88
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners